Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Calliditas Therapeutics stock

Learn how to easily invest in Calliditas Therapeutics stock.

Calliditas Therapeutics is a biotechnology business based in the US. Calliditas Therapeutics shares (CALT) are listed on the NASDAQ and all prices are listed in US Dollars. Calliditas Therapeutics employs 137 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Calliditas Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CALT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Calliditas Therapeutics stock price (NASDAQ: CALT)

Use our graph to track the performance of CALT stocks over time.

Calliditas Therapeutics shares at a glance

Information last updated 2022-09-26.
Latest market close$14.15
52-week range$12.55 - $27.50
50-day moving average $17.82
200-day moving average $18.75
Wall St. target price$61.75
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) N/A

Buy Calliditas Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 8 of 8
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Calliditas Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Calliditas Therapeutics price performance over time

Historical closes compared with the close of $14.15 from 2022-09-26

1 week (2022-09-20) -5.73%
1 month (2022-08-26) -11.62%
3 months (2022-06-28) -20.21%
6 months (2022-03-28) -22.53%
1 year (2021-09-28) -34.85%
2 years (2020-09-28) -41.04%
3 years (2019-09-24) N/A
5 years (2017-09-24) N/A

Calliditas Therapeutics financials

Gross profit TTM $229.3 million
Return on assets TTM -29.11%
Return on equity TTM -72.35%
Profit margin -177.21%
Book value N/A
Market capitalisation $365.1 million

TTM: trailing 12 months

Calliditas Therapeutics share dividends

We're not expecting Calliditas Therapeutics to pay a dividend over the next 12 months.

Calliditas Therapeutics share price volatility

Over the last 12 months, Calliditas Therapeutics's shares have ranged in value from as little as $12.55 up to $27.5. A popular way to gauge a stock's volatility is its "beta".

CALT.US volatility(beta: 1.41)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Calliditas Therapeutics's is 1.4058. This would suggest that Calliditas Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Calliditas Therapeutics overview

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden. .

Frequently asked questions

What percentage of Calliditas Therapeutics is owned by institutions?
Currently 3.291% of Calliditas Therapeutics shares are held by institutions.
How many people work for Calliditas Therapeutics?
Latest data suggests 137 work at Calliditas Therapeutics.
When does the fiscal year end for Calliditas Therapeutics?
Calliditas Therapeutics's fiscal year ends in December.
Where is Calliditas Therapeutics based?
Calliditas Therapeutics's address is: Kungsbron 1, D5, Stockholm, Sweden, 111 22
What is Calliditas Therapeutics's ISIN number?
Calliditas Therapeutics's international securities identification number is: US13124Q1067

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site